Arvinas, Inc. (ARVN)
|52 Week Range||13.57-39.31|
|1y Target Est||-|
|DCF Unlevered||ARVN DCF ->|
|DCF Levered||ARVN LDCF ->|
|Debt / Equity||0.87%||Neutral|
Upgrades & Downgrades
Latest ARVN news
Arvinas to Host Conference Call and Webcast to Discuss Vepdegestrant (ARV-471) Data Presented at 202...
5 December 2023
NEW HAVEN, Conn., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today anno...
Does Arvinas, Inc. (ARVN) Have the Potential to Rally 145.52% as Wall Street Analysts Expect?
1 December 2023
The average of price targets set by Wall Street analysts indicates a potential upside of 145.5% in Arvinas, Inc. (ARVN). While the effectiveness of this highly sought-after metric is questionable, the...
Arvinas: Protein Degradation Pioneer Presents An Intriguing Speculative Buy Opportunity
24 November 2023
Arvinas is a leading company in developing protein degraders, with a depressed share price, drugs in advanced study phases, and ample cash reserves. Arvinas is focused on oncology, particularly breast...
Arvinas, Inc. (ARVN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
13 November 2023
Arvinas, Inc. (ARVN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among ...
Strength Seen in Arvinas, Inc. (ARVN): Can Its 6.3% Jump Turn into More Strength?
31 October 2023
Arvinas, Inc. (ARVN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near ter...
Arvinas' Potential In Treating ER+, HER2- Breast Cancer
4 September 2023
Arvinas focuses on protein degradation therapies, with current projects targeting breast and prostate cancers. Financially, ARVU holds robust liquidity, minimal debt, and a cash runway till 2026; comb...
Arvinas to Participate in Upcoming Investor Conferences
1 September 2023
NEW HAVEN, Conn., Sept. 01, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today ann...
Arvinas, Inc. (ARVN) Reports Q2 Loss, Tops Revenue Estimates
8 August 2023
Arvinas, Inc. (ARVN) came out with a quarterly loss of $1.25 per share versus the Zacks Consensus Estimate of a loss of $1.67. This compares to loss of $1.32 per share a year ago.
Arvinas, Inc. (ARVN) Moves 17.5% Higher: Will This Strength Last?
13 June 2023
Arvinas, Inc. (ARVN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down t...